Arcadia Biosciences R&D Spending Growth & History (RKDA)
Arcadia Biosciences's r&d spending was $9,000 for fiscal 2025.
View full Arcadia Biosciences company overviewArcadia Biosciences annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9,000 | −$44,000 | −83.02% |
| 2024 | 2024-12-31 | $53,000 | −$11,000 | −17.19% |
| 2023 | 2023-12-31 | $64,000 | −$1.4M | −95.76% |
| 2022 | 2022-12-31 | $1.5M | −$2.4M | −61.20% |
| 2021 | 2021-12-31 | $3.9M | −$4.1M | −51.14% |
| 2020 | 2020-12-31 | $8.0M | $862,000 | +12.14% |
| 2019 | 2019-12-31 | $7.1M | $1.0M | +16.96% |
| 2018 | 2018-12-31 | $6.1M | −$1.3M | −18.06% |
| 2017 | 2017-12-31 | $7.4M | −$1.3M | −14.50% |
| 2016 | 2016-12-31 | $8.7M | −$303,000 | −3.38% |
| 2015 | 2015-12-31 | $9.0M | −$1.0M | −10.45% |
| 2014 | 2014-12-31 | $10.0M | — | — |
Arcadia Biosciences quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | −$9,000 | — |
| Q4 2025 | 2025-12-31 | $0 | −$13,000 | — |
| Q3 2025 | 2025-09-30 | $0 | −$24,000 | — |
| Q2 2025 | 2025-06-30 | $9,000 | −$1,000 | −10.00% |
| Q1 2025 | 2025-03-31 | $0 | −$6,000 | — |
| Q4 2024 | 2024-12-31 | $13,000 | — | — |
| Q3 2024 | 2024-09-30 | $24,000 | $9,000 | +60.00% |
| Q2 2024 | 2024-06-30 | $10,000 | −$17,000 | −62.96% |
| Q1 2024 | 2024-03-31 | $6,000 | −$353,000 | −98.33% |
| Q3 2023 | 2023-09-30 | $15,000 | −$240,000 | −94.12% |
| Q2 2023 | 2023-06-30 | $27,000 | −$332,000 | −92.48% |
| Q1 2023 | 2023-03-31 | $359,000 | −$36,000 | −9.11% |
| Q4 2022 | 2022-12-31 | $500,000 | −$61,000 | −10.87% |
| Q3 2022 | 2022-09-30 | $255,000 | −$783,000 | −75.43% |
| Q2 2022 | 2022-06-30 | $359,000 | −$772,000 | −68.26% |
| Q1 2022 | 2022-03-31 | $395,000 | −$764,000 | −65.92% |
| Q4 2021 | 2021-12-31 | $561,000 | −$1.4M | −71.39% |
| Q3 2021 | 2021-09-30 | $1.0M | −$724,000 | −41.09% |
| Q2 2021 | 2021-06-30 | $1.1M | −$862,000 | −43.25% |
| Q1 2021 | 2021-03-31 | $1.2M | −$1.1M | −48.35% |
| Q4 2020 | 2020-12-31 | $2.0M | $249,000 | +14.54% |
| Q3 2020 | 2020-09-30 | $1.8M | −$169,000 | −8.75% |
| Q2 2020 | 2020-06-30 | $2.0M | $43,000 | +2.21% |
| Q1 2020 | 2020-03-31 | $2.2M | $739,000 | +49.10% |
| Q4 2019 | 2019-12-31 | $1.7M | $167,000 | +10.81% |
| Q3 2019 | 2019-09-30 | $1.9M | $597,000 | +44.75% |
| Q2 2019 | 2019-06-30 | $1.9M | $156,000 | +8.70% |
| Q1 2019 | 2019-03-31 | $1.5M | $109,000 | +7.81% |
| Q4 2018 | 2018-12-31 | $1.5M | −$621,000 | −28.67% |
| Q3 2018 | 2018-09-30 | $1.3M | −$415,000 | −23.73% |
| Q2 2018 | 2018-06-30 | $1.8M | $125,000 | +7.49% |
| Q1 2018 | 2018-03-31 | $1.4M | −$427,000 | −23.42% |
| Q4 2017 | 2017-12-31 | $2.2M | $176,000 | +8.84% |
| Q3 2017 | 2017-09-30 | $1.7M | −$506,000 | −22.44% |
| Q2 2017 | 2017-06-30 | $1.7M | −$547,000 | −24.68% |
| Q1 2017 | 2017-03-31 | $1.8M | −$379,000 | −17.21% |
| Q4 2016 | 2016-12-31 | $2.0M | $121,000 | +6.47% |
| Q3 2016 | 2016-09-30 | $2.3M | −$924,000 | −29.07% |
| Q2 2016 | 2016-06-30 | $2.2M | $130,000 | +6.23% |
| Q1 2016 | 2016-03-31 | $2.2M | $370,000 | +20.20% |
| Q4 2015 | 2015-12-31 | $1.9M | −$201,000 | −9.71% |
| Q3 2015 | 2015-09-30 | $3.2M | −$505,000 | −13.71% |
| Q2 2015 | 2015-06-30 | $2.1M | −$189,000 | −8.31% |
| Q1 2015 | 2015-03-31 | $1.8M | −$151,000 | −7.61% |
| Q4 2014 | 2014-12-31 | $2.1M | — | — |
| Q3 2014 | 2014-09-30 | $3.7M | — | — |
| Q2 2014 | 2014-06-30 | $2.3M | — | — |
| Q1 2014 | 2014-03-31 | $2.0M | — | — |
Arcadia Biosciences r&d spending trends
Over the last five fiscal years, Arcadia Biosciences's r&d spending decreased from $8.0M to $9,000, a change of −$8.0M. The latest reported quarter, Q2 2026, shows $0.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcadia Biosciences source filings ↗